Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial

The safety and immunogenicity of a new candidate tuberculosis (TB) vaccine, FP85A was evaluated alone and in heterologous prime-boost regimes with another candidate TB vaccine, MVA85A. This was an open label, non-controlled, non-randomized Phase I clinical trial. Healthy previously BCG-vaccinated ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowland, Rosalind, Pathan, Ansar A., Satti, Iman, Poulton, Ian D., Matsumiya, Magali M. L., Whittaker, Megan, Minassian, Angela M., O’Hara, Geraldine A., Hamill, Matthew, Scott, Janet T., Harris, Stephanie A., Poyntz, Hazel C., Bateman, Cynthia, Meyer, Joel, Williams, Nicola, Gilbert, Sarah C., Lawrie, Alison M., Hill, Adrian V.S., McShane, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667946/
https://www.ncbi.nlm.nih.gov/pubmed/23143773
http://dx.doi.org/10.4161/hv.22464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667946/
https://www.ncbi.nlm.nih.gov/pubmed/23143773
http://dx.doi.org/10.4161/hv.22464

Ejemplares similares